Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹379 Cr revenue.
COGS 44.3%, employees 16.0%.
“March 2026, as you mentioned, remains a firm timeline for EU GMP audit?”
“And regarding the EU, compliance, so, I mean, I'm sure your your consultant would have given also an outside limit in terms of what can be the timeline.”
“we expect the 2026 revenues to be in the range of FY 2025 revenues broadly in line with last year.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 2.8%▼ | 10.5% |
| ROCE | 7.8%▼ | 13.8% |
| Net Margin | 1.8%▼ | 8.7% |
| EBITDA Margin | 11.5%▼ | 16.0% |
| Debt To Equity | 0.47x▲ | 0.21x |
| Rev Growth 3yr | 4.4%▼ | 5.8% |
| EPS Growth 3yr | -5.8%▼ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹378 Cr -0.3% | ₹379 Cr +3.2% | ₹367 Cr -7.8% | ₹399 Cr +19.5% | ₹333 Cr +8.5% | ₹307 Cr +10.6% | ₹278 Cr -17.2% | ₹335 Cr |
| Other Income | ₹7 Cr +19.8% | ₹6 Cr +11.6% | ₹5 Cr -19.2% | ₹6 Cr +45.7% | ₹4 Cr +88.4% | ₹2 Cr -48.3% | ₹5 Cr +120.6% | ₹2 Cr |
| Total Income | ₹385 Cr -0.0% | ₹385 Cr +3.3% | ₹373 Cr -8.0% | ₹405 Cr +19.9% | ₹338 Cr +9.1% | ₹310 Cr +9.7% | ₹282 Cr -16.3% | ₹337 Cr |
| COGS | ₹167 Cr -0.8% | ₹168 Cr -2.1% | ₹171 Cr -13.8% | ₹199 Cr +24.0% | ₹160 Cr +1.1% | ₹159 Cr +10.8% | ₹143 Cr -10.3% | ₹160 Cr |
| ₹373 Cr +1.8% | ₹367 Cr +5.1% | ₹349 Cr -5.6% | ₹370 Cr +16.7% | ₹317 Cr +7.7% | ₹294 Cr +4.3% | ₹282 Cr -10.5% | ₹315 Cr | |
| Profit Before Tax | ₹11 Cr -36.8% | ₹18 Cr -23.8% | ₹24 Cr -33.1% | ₹35 Cr +68.0% | ₹21 Cr +105.7% | ₹10 Cr | ₹0.07 Cr -99.7% | ₹22 Cr |
| ₹4 Cr -24.8% | ₹6 Cr -8.6% | ₹6 Cr -41.4% | ₹11 Cr +68.2% | ₹6 Cr +122.8% | ₹3 Cr ↑ Recovery | (₹3 Cr) ↓ Decline | ₹7 Cr | |
| Net Profit | ₹7 Cr -42.6% | ₹12 Cr -29.5% | ₹17 Cr -29.4% | ₹24 Cr +67.9% | ₹15 Cr +98.8% | ₹7 Cr +122.0% | ₹3 Cr -78.5% | ₹15 Cr |
| Profit (Owners) | ₹7 Cr -42.6% | ₹12 Cr -29.5% | ₹17 Cr -29.4% | ₹24 Cr +67.9% | ₹15 Cr +111.9% | ₹7 Cr +108.3% | ₹3 Cr -78.5% | ₹15 Cr |
| Minority Interest | (₹0.00 Cr) -50.0% | (₹0.00 Cr) -100.0% | (₹0.00 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹1 Cr ↑ Recovery | (₹0.03 Cr) +89.0% | (₹0.25 Cr) ↓ Decline | ₹0.68 Cr +65.5% | ₹0.41 Cr ↑ Recovery | (₹0.45 Cr) ↓ Decline | ₹0.34 Cr -30.5% | ₹0.49 Cr |
| EPS | ₹1.43 | ₹2.50 | ₹3.54 | ₹5.01 | ₹2.99 | ₹1.41 | ₹0.68 | ₹3.17 |
| Diluted Shares | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Zim Laboratories Limited has informed the Exchange about Schedule of meet
Zim Laboratories Limited has informed the Exchange about Schedule of meet
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication-Corrigendum
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Zim Laboratories Limited has informed the Exchange about Transcript
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Zim Laboratories Limited has informed the Exchange regarding Change in Auditors of the company.
Zim Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Zim Laboratories Limited has informed the Exchange regarding Allotment of 48726 Shares.
Zim Laboratories Limited has informed the Exchange regarding allotment of 4764497 securities pursuant to Preferential Issue at its meeting held on March 13, 2026
Zim Laboratories Limited has informed the Exchange about Closure of the step down subsidiary of the Company
Zim Laboratories Limited has informed the Exchange about Credit Rating
Zim Laboratories Limited has informed the Exchange about Transcript
Zim Laboratories Limited has submitted the Exchange a copy Srutinizers report of Extraordinary General Meeting held on February 16, 2026. Further, the company has informed the Exchange regarding voti...